AG
MYGN icon

Aperio Group’s Myriad Genetics MYGN Stock Holding History

Aperio Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$417K Buy
21,088
+770
+4% +$12.4K ﹤0.01% 2044
2020
Q3 		$265K Sell
20,318
-4,658
-19% -$59K ﹤0.01% 2120
2020
Q2 		$283K Buy
24,976
+853
+4% +$12.1K ﹤0.01% 2052
2020
Q1 		$345K Buy
24,123
+6,962
+41% +$147K ﹤0.01% 1833
2019
Q4 		$467K Sell
17,161
-4,019
-19% -$111K ﹤0.01% 1845
2019
Q3 		$606K Sell
21,180
-635
-3% -$18.5K ﹤0.01% 1649
2019
Q2 		$606K Sell
21,815
-3,790
-15% -$107K ﹤0.01% 1666
2019
Q1 		$850K Buy
25,605
+2,276
+10% +$69.3K ﹤0.01% 1441
2018
Q4 		$678K Buy
23,329
+5,854
+33% +$211K ﹤0.01% 1513
2018
Q3 		$804K Buy
17,475
+1,648
+10% +$73.3K ﹤0.01% 1529
2018
Q2 		$591K Buy
15,827
+924
+6% +$31.2K ﹤0.01% 1664
2018
Q1 		$440K Buy
14,903
+662
+5% +$22.4K ﹤0.01% 1753
2017
Q4 		$489K Buy
14,241
+2,509
+21% +$84.6K ﹤0.01% 1714
2017
Q3 		$424K Sell
11,732
-397
-3% -$11.3K ﹤0.01% 1738
2017
Q2 		$313K Buy
12,129
+534
+5% +$11.3K ﹤0.01% 1871
2017
Q1 		$223K Buy
+11,595
New +$205K ﹤0.01% 1986
2016
Q3 		– Sell
-11,577
Closed -$354K – 2076
2016
Q2 		$354K Sell
11,577
-1,481
-11% -$51.5K ﹤0.01% 1584
2016
Q1 		$489K Buy
13,058
+1,805
+16% +$68K ﹤0.01% 1381
2015
Q4 		$486K Buy
11,253
+323
+3% +$13.6K ﹤0.01% 1348
2015
Q3 		$410K Buy
10,930
+651
+6% +$23.1K ﹤0.01% 1416
2015
Q2 		$349K Buy
10,279
+1,084
+12% +$36.9K ﹤0.01% 1538
2015
Q1 		$326K Buy
9,195
+1,250
+16% +$44.7K ﹤0.01% 1519
2014
Q4 		$271K Sell
7,945
-1,183
-13% -$42K ﹤0.01% 1574
2014
Q3 		$352K Buy
9,128
+676
+8% +$25.2K ﹤0.01% 1308
2014
Q2 		$329K Sell
8,452
-66
-0.8% -$2.46K ﹤0.01% 1345
2014
Q1 		$291K Buy
+8,518
New +$264K ﹤0.01% 1643
2013
Q3 		– Sell
-7,684
Closed -$206K – 1809
2013
Q2 		$206K Buy
+7,684
New +$223K ﹤0.01% 1487

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aperio Group's MYGN Position: Q4 2020 in Review

Aperio Group increased its Myriad Genetics (MYGN) stake by 3.8% in Q4 2020, buying an estimated $12.4K and bringing the position to 21,088 shares worth $417K. The position accounts for ﹤0.01% of the portfolio, ranked #2044.

Aperio Group first reported a position in MYGN in Q2 2013 and has held it in 27 quarters since. The position peaked at $850K in Q1 2019. 187 funds tracked by Wall St. Rank hold MYGN as of Q4 2020.

  • Aperio Group held 21,088 shares of Myriad Genetics worth $417K as of Q4 2020.
  • Aperio Group bought 770 Myriad Genetics shares in Q4 2020, an estimated $12.4K.
  • Myriad Genetics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2044 holding.
  • Aperio Group first reported a position in Myriad Genetics in Q2 2013 and has held it in 27 quarters since.
  • Aperio Group's Myriad Genetics position peaked at $850K in Q1 2019.
  • 187 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.